

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/78		A1	(11) International Publication Number: WO 99/24047 (43) International Publication Date: 20 May 1999 (20.05.99)
<p>(21) International Application Number: PCT/CA98/01035</p> <p>(22) International Filing Date: 5 November 1998 (05.11.98)</p> <p>(30) Priority Data: 2,220,633 7 November 1997 (07.11.97) CA</p> <p>(71) Applicant (<i>for all designated States except US</i>): McGILL UNIVERSITY [CA/CA]; 845 Sherbrooke Street West, Montréal, Québec H3A 2T5 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): ALAOUI-JAMALI, Moulay, Abdellah [CA/CA]; 1745 rue Taschereau, Duvemay, Laval, Québec H7G 2P1 (CA). BATIST, Gerald [CA/CA]; 4670 Grosvenor Street, Montréal, Québec H3W 2L8 (CA). ZAMIR, Lolita [CA/CA]; 810 Upper Lansdowne, Westmount, Québec H3Y 1J8 (CA).</p> <p>(74) Agents: COTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).</p>			<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: ECHINOPS EXTRACT WITH ANTI-CANCER ACTIVITY</p> <p>(57) Abstract</p> <p>The present invention relates to an extract of <i>Echinops spinosus L. (Asteraceae)</i> and organic solvent soluble fractions of the extract that may be used in the treatment of cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ECHINOPS EXTRACT WITH ANTI-CANCER ACTIVITY

BACKGROUND OF THE INVENTION(a) Field of the Invention

5 The invention relates to an extract of *Echinops spinosus L.* (Asteraceae) and fractions thereof for use in the treatment of cancer; the invention also relates to the preparation of the extract and the fractions and pharmaceutical compositions containing them.

10 (b) Description of Prior Art

Cancers are uncontrolled cell proliferations that result from the accumulation of genetic changes in cells endowed with proliferative potential. After a variable latency period during which they are clinically silent, the malignant cells progress to aggressive invasive and metastatic stages with tumor formation, bleeding, susceptibility to infections, and widespread dissemination throughout the body.

Despite important advances in treatment, cancers still account for 28% of death in Western countries. Treatment of cancer has relied mainly on surgery, chemotherapy, radiotherapy and more recently immunotherapy. Significant improvement in outcome has occurred with the use of combined modalities, for a small number of cancers. However, for the most frequent types of cancers (lung, breast, colo-rectal and the leukemias) complete remission and cure has not been achieved. Therefore, the development of new approaches for treating cancer patients is critically needed particularly for those patients whose disease has progressed to a metastatic stage and are refractory to standard chemotherapy.

The leaves of *Echinops spinosus L.* (Asteraceae) have previously been used in local or herbal medicine to treat warts; and a peptide having vasoconstrictive

properties has been isolated from the root of the plant.

It would be highly desirable to be provided with a novel therapy for cancer which overcome the drawbacks
5 of the method of the prior art.

SUMMARY OF THE INVENTION

One aim of the present invention is to provide a dried extract of the roots of *Echinops spinosus* L.
10 (Asteraceae) and fractions thereof have been found to be useful in treating cancers.

In accordance with one aspect of the invention there is provided an anti-cancer pharmaceutical composition comprising an acceptable, effective anti-cancer
15 amount of an extract of roots *Echinops spinosus* L. (Asteraceae) or an organic solvent soluble fraction thereof, in association with a pharmaceutically acceptable carrier.

In accordance with another aspect of the invention
20 there is provided an extract of roots of *Echinops spinosus* L. (Asteraceae) or an organic solvent soluble fraction thereof, for use in the treatment of cancer.

In accordance with yet another aspect of the invention there is provided a method of treating cancer
25 comprising administering to a patient, an acceptable, effective anti-cancer amount of an extract of roots of *Echinops spinosus* L. (Asteraceae) or an organic solvent soluble fraction thereof.

In accordance with still another aspect of the invention there is provided a method of producing an anti-cancer agent comprising organic solvent extraction
30 of an extract of roots of *Echinops spinosus* L. (Asteraceae) to produce an organic solvent soluble extract, and chromatographic separation of fractions of said
35 organic solvent soluble extract.

For the purpose of the present invention the following terms are defined below.

The term "anti-cancer therapy" is intended to
5 mean growth inhibition/eradication of primary tumors,
stabilization of tumor growth, inhibition of metastasis
formation, or prevention of tumor formation. Furthermore,
anticancer activity also covers any combination
between our substances and other known or investiga-
10 tional anticancer agents, in order to improve the
therapeutic efficacy of drugs.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A illustrates the *in vitro* cytotoxicity of various fractions using human breast adenocarcinoma cell line, MCF7;

Fig. 1B illustrates the *in vitro* cytotoxicity of various fractions using human ovarian adenocarcinoma cell line, A2780;

Fig. 2 illustrates the Lung Lewis carcinoma model schedule for drug treatment and also the antimetastatic activity of 75B;

Fig. 3 illustrates a schedule for drug treatment showing that doses used for the antimetastatic study have minor toxic effects to the host, since toxicity
25 was observed only with very high doses >300; and

Fig. 4 illustrates a schematic representation of the process of fractionation.

DETAILED DESCRIPTION OF THE INVENTION

30 The organic solvent soluble fractions of the present invention are fractions soluble in organic solvents such as methanol, ethanol, ethyl acetate and dimethyl sulfoxide.

The invention is more especially concerned with the fractions which are soluble in the organic solvents but not soluble in water.

- i) Extract of *Echinops spinosus* L. (Asteraceae)
5 ii) Fractions

The dried extract of *Echinops spinosus* L. (Asteraceae) is first treated with water to remove water soluble fractions of the extract, whereafter the residue is treated with an organic solvent, for example, ethyl acetate to dissolve the organic solvent soluble fractions.

10 The ethyl acetate soluble fractions are purified, for example, on charcoal and/or CELITE™ (trademark for diatomaceous earth) and individual fractions
15 are separated by high-performance liquid chromatography.

The fractions recovered were dissolved in dimethyl sulfoxide or ethanol.

20 The samples when stored at -80°C retained their activity even after four months.

25 The organic solvent soluble fractions and extract were found to have a strong antiproliferative activity in a panel of human cancer cell lines derived from breast, ovary, prostate and lung. *In vivo*, the fractions and extract demonstrate antimetastatic activity in animal models.

The process of fractionation is illustrated schematically in Fig. 4.

30 The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLE IIn vitro antiproliferative activityCell lines and cell culture

Two cell lines were used to test for the anti-proliferative activity of various fractions: human ovarian adenocarcinoma cell line A2780, and the human breast cancer cell line MCF7. Cells were grown in RPMI medium supplemented with 10% fetal bovine serum and penicillin-streptomycin antibiotics. Cells were maintained in culture at 37°C in an atmosphere of 5% CO₂.

Cytotoxicity assay

Exponentially growing cells ($2-3 \times 10^3$ cells/100 µl) were seeded in 96-well plates and incubated for 16h. Cells were then treated continuously with the fractions. 72h later, cell survival was evaluated by replacing the culture media with 150 µl fresh medium containing 10 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid buffer, pH 7.4 and 50 µl of 2.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) in PBS, pH 7.4, were then added. After 3-4 h of incubation at 37°C, the medium and MTT were removed, and 200 µl of DMSO (dimethyl sulfoxide) was added to dissolve the precipitate of reduced MTT, followed by addition of 25 µl glycine buffer (0.1M glycine plus 0.1M NaCl, pH 10.5). The formazan crystals were then dissolved and the absorbance was determined at 570 nm with a microplate reader (BIORAD, model 450). The MTT assay distinguishes between viable and non-viable cells on the basis that physiologically active mitochondria metabolizes the MTT only in viable cells. The IC₅₀ was calculated as the concentration of drug causing a 50% inhibition in the absorbance compared to cells treated with solvent alone.

Apoptosis assay

Cells were seeded at 1×10^6 cells/T75 cm² plate, then left to attach overnight. The cells were then continuously exposed to the extracts for 72 hrs.

5 Cells were then collected and washed 2x with PBS and then diluted to $1 \times 10^6/100 \mu\text{l}$ PBS and placed in 96 well plate. Fixation was performed with 200 ml of 70% Ethanol with shaking at 4°C for 30 min. Cells were then washed 1x with PBS, and permeabilized with 1% TRITON™
10 x-100 in 0.1% sodium citrate on ice for 2 min. Cells were washed 2x with PBS, and then labeled in 50 ml/well TUNEL reaction mixture of the Boehringer Mannheim In Situ cell death detection kit at 37°C in the dark for 1hr. Cells were then washed 3x with 1% BSA in PBS and
15 resuspended in 500 μl PBS for analysis by flow cytometry. The cell death Tunnel assay estimates the extent of DNA fragmentation. The fragmented DNA is labeled at the free 3' OH group using terminal deoxynucleotide transferase. Fluoroscein labels are incorporated into
20 nucleotide polymers that are attached to the DNA fragments. The labeling is specific to fragmented DNA and not degraded DNA due to the required presence of the 3' OH group. Thus, the level of fluorescence as measured by a flow cytometer is correlated to the level of DNA
25 fragmentation, and hence to the number of apoptotic cells.

Results

Methanol soluble fractions, but not water soluble fractions, was found to have a potent antiproliferative activity in both A2780 and MCF7 cell lines.
30 Further chromatographic fractionation of these organic soluble extract led to the isolation of 12 fractions referred to as E1-E12 (Figs. 1A and 1B).

Morphological changes of cells treated with E
35 fractions resembled those described with apoptosis-

mediated cell death. Apoptosis was examined using ladder DNA and TUNEL Assays; it was found that some fractions, e.g. E4 and E5, induce apoptosis.

5

EXAMPLE II*In vivo study*Lewis lung carcinoma cell line and cell culture

The Lewis lung carcinoma clone, M47, with a high metastatic potential to the lung, was established 10 and characterized (Brodt P., Cancer Res., 46: 2442, 1986). These cells were confirmed to be free of mycoplasma infection. Cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, under 5% CO₂. Cells were passed twice a week. Stocks of cells were generated and stored as early passages (passage no. 8-10 considering 15 the initial stock received as passage no. 1). Cells were then propagated and stocks of the same passages were established and stored in liquid nitrogen for further studies with AETERNA compounds.

For tumor induction, cells were grown to 70% confluence in complete medium and then collected using trypsin-EDTA solution [0.05% trypsin, 0.53 mM EDTA-4Na in H_BSS without Ca⁺⁺, Mg⁺⁺, and NaHCO₃; Cellgro no. 25-25 052-Li]. Cells were then centrifuged and washed three times with phosphate buffer solution [D-PBS, Ca⁺⁺ and Mg⁺⁺ free; Cellgro no. 21-031-LV], and resuspended at a dilution of 0.1 to 1x10⁶ cells/0.1ml. Viability was examined by trypan blue staining and only flasks in 30 which the viability was >95% were used for in vivo studies.

The mouse strain used in this study is C57BL/10 from the research laboratories. The animal room used has two doors, one serving as the entrance, and the 35 other door provides direct access to wash-

ing/sterilization/incineration facilities; it permits accurate adjustment of environmental parameters including temperature, humidity, ventilation, and lighting. Cleaning and sanitation practices are performed, on a 5 daily basis, by personnel with appropriate training.

Tumor cell inoculation and treatment

Animals were housed 5 per cage and were fed a diet of animal chow and water ad libitum. After one week acclimatization, LLC cells were transplanted subcutaneously, as a suspension of tumor cells [2-5x10⁵ viable cells per 0.1ml], in the axillary region of the right flank. All animals were inoculated at the same site. Animals were subjected, on a daily basis, to general examination. Tumor growth was monitored every 10 second or third day using calipers. Parameters measured are: tumor measured along the longest axis (length) and the perpendicular shortest axis (width) and the relative tumor volume (in cm³) was calculated by the formula: [Length (cm) x (width cm)²]/2. When the tumor 15 reaches a size of 0.5-1.0 cm² (approximately 2-3 weeks), mice were randomized into three groups.

Animals were subjected to surgery to remove the primary tumor. The mice were lightly anesthetized with Forane. The skin overlying the tumor was cleaned with 20 betadine and ethanol, in a laminar flow hood. A small skin incision (0.5-1cm) was made using a sterile scalpel, and the tumor was carefully separated from the normal tissues (skin and muscle). LLC (at early stage 25 of growth; 1-3 weeks) is well localized tumor and separation was easy to achieve without any significant damage to normal tissues. The tumor was removed, weighed and fixed for histopathology purposes. The wound was closed with surgical stainless steel clips (Autoclips; 30 9mm; Clay Adams, Inc., Parsippany, NJ). This site was

further disinfected with betadine and the animal was housed as described above.

Mice were randomized after surgery into a group of 5 per cage. Cages were randomly assigned to specific 5 experimental groups. The mice were then labeled by numbers using the "ear punching" method. Mice were checked on a daily basis to ensure the absence of infection. Animals with discomfort were sacrificed immediately. An additional extra-group of control mice was included to 10 determine the optimal timing for sacrifice in order to obtain a significant number of well localized lung metastases. This group was subjected to the same experimental procedure as group 1 with the exception of drug treatment. Based on this group, a period of two 15 weeks after removal of the primary tumor was sufficient to obtain an average of 20-30 nodules on the lung surface. Therefore, a two week period after primary tumor removal was used to sacrifice treated mice.

Dosing schedule and treatment

20 Drugs were given by gavage, using a 22G curved feeding needle [total volume of 0.5ml per animal], on a single daily basis administration after tumor cell inoculation. Control animals were given the same volume of saline solution [0.9% sodium chloride; Abbott Lab., 25 lot no. 12 455 WS]. The dose of each drug was normalized to an average of 20g body weight per animal. The schedules for drug treatment were based upon conditions described in Figs. 2 and 3.

Animal sacrifice, tumor/organs preparation

30 At the end of each experiment (a total of 5-8 weeks), animals were sacrificed in a CO₂ Chamber and autopsied. Tumors, organs or both were removed under sterile conditions [using a laminar flow hood]. Tumors were weighed. Organs (5 per group) were examined for 35 gross pathological changes and then fixed in 10% forma-

lin. Lungs were fixed in 10% Bouin's fixative diluted in a formalin solution, and lung surface metastases were counted using a stereomicroscope at 4x magnification or a magnifying-glass, and then lungs were embedded in paraffin wax according to standard procedures. Embedded tissues were stored for future histopathological studies.

Statistical analysis

The unpaired Student t-test was used to compare statistical significance among various groups.

Results

Methanol soluble fraction was found to have a good antimetastatic activity in the Lewis lung carcinoma model. A dose relationship was also observed (see Figs. 2 and 3).


While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:


1. An anti-cancer pharmaceutical composition comprising an acceptable, effective anti-cancer amount of an extract of roots of *Echinops spinosus L.* (Asteraceae) or an organic solvent soluble fraction thereof, in association with a pharmaceutically acceptable carrier.
2. An extract of roots of *Echinops spinosus L.* (Asteraceae) or an organic solvent soluble fraction thereof, for use in the treatment of cancer.
3. A method of treating cancer comprising administering to a patient, an acceptable, effective anti-cancer amount of an extract of roots of *Echinops spinosus L.* (Asteraceae) or an organic solvent soluble fraction thereof.
4. A method of producing an anti-cancer agent comprising an organic solvent extraction of an extract of roots of *Echinops spinosus L.* (Asteraceae) to produce an organic solvent soluble extract, and chromatographic separation of fractions of said organic solvent soluble extract.


1/4


Human Breast Adenocarcinoma Cell line, MCF7




Human Ovarian Adenocarcinoma Cell line, A2780







4/4



NB: P5X3 and AN-1502 are various batches of 75B

~~FIGURE~~ - 4

INTERNATIONAL SEARCH REPORT

Inte...onal Application No
PCT/CA 98/01035

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. BOST ET AL.: "SUR QUELQUES PROPRIÉTÉS PHARMACODYNAMIQUES D'ECHINOPS SPINOSUS L." BULLETIN DE L'ACADEMIE VÉTÉRINAIRE DE FRANCE, vol. 27, no. 2, February 1954, pages 87-93, XP002093049 see the whole document -----	1
X,P	HORVÁTH ZSOLT ET AL.: "ECHINOPS FAJOK POLISZACHARIDJAINAK TANULMÁNYOZÁSA GYÓGYNÖVÉNY POLISZACHARIDOK I." ACTA PHARMACEUTICA HUNGARICA, vol. 68, July 1998, pages 214-219, XP002093050 see abstract ----- -/-	1-4

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 February 1999

Date of mailing of the international search report

24/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

INTERNATIONAL SEARCH REPORT

Inte .onal Application No

PCT/CA 98/01035

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR 1 519 063 A (VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY INSTITUT LEKARSTVENNYKH RASTENY) 10 July 1968 -----	
A	FR 2 177 628 A (FRANCAISE COOP PHARMA) 9 November 1973 -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01035

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 3
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claim 3 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 3

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Search Application No

PCT/CA 98/01035

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 1519063	A 10-07-1968	NONE	
FR 2177628	A 09-11-1973	NONE	